-
Product Insights
Inclusion Body Myositis (IBM) – Drugs In Development, 2023
Global Markets Direct’s, ‘Inclusion Body Myositis (IBM) - Drugs In Development, 2023’, provides an overview of the Inclusion Body Myositis (IBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Hereditary Inclusion Body Myopathy (h-IBM) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hereditary Inclusion Body Myopathy (h-IBM) - Drugs In Development, 2023’, provides an overview of the Hereditary Inclusion Body Myopathy (h-IBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hereditary Inclusion Body Myopathy (h-IBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
IBM Gunbarrel facility Solar PV Park
IBM Gunbarrel facility Solar PV Park is a solar PV project located in Minnesota, United States. The project is owned and developed by NextEra Energy Inc. The project came online in 2019. Empower your strategies with our IBM Gunbarrel facility Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ulviprubart in Inclusion Body Myositis (IBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulviprubart in Inclusion Body Myositis (IBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ulviprubart in Inclusion Body Myositis (IBM) Drug Details: Ulviprubart...
-
Thematic Analysis
NewIT Services Sector Scorecard, Q1 2024 Update – Thematic Intelligence
Companies scoring well in the cloud, data analytics, and future of work themes lead the thematic screen of GlobalData’s IT services sector scorecard. This is dominated by the global IT services giants Accenture, IBM, and Infosys, closely followed by Capgemini and Tata Consultancy Services (TCS). Indian heritage vendors occupy half of the top 10 vendor positions, suggesting they are successfully adapting their strategies to the long-term concern of a declining cost advantage versus their US and European peers.
-
Thematic Analysis
NewApplication Software Sector Scorecard, Q1 2024 Update – Thematic Intelligence
Companies scoring well in the artificial intelligence (AI), big data, and cloud computing-related themes lead the thematic screen of GlobalData’s application software sector scorecard. This screen is dominated by the large US cloud vendors (Microsoft, Amazon, and Alphabet), but also includes leading enterprise software companies such as IBM, SAP, and Infor, as well as Apple. There have been minor score changes for companies such as Broadcom, OpenText, and Software AG due to their divestitures following recent acquisitions.
-
Thematic Analysis
NewCloud Services Sector Scorecard, Q1 2024 Update – Thematic Intelligence
The thematic screen of GlobalData’s cloud services sector scorecard is led by the global hyperscalers Microsoft and Amazon, with Alphabet and IBM also in the top 10. Microsoft and Alphabet, in particular, are aggressively investing in generative artificial intelligence (AI), developing foundational large language models (LLM), and building the infrastructure to offer related services to customers. In recent months, Alphabet launched its Gemini AI model, Microsoft launched its own AI chips and also invested in Mistral, and Microsoft’s strategic partner...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Froniglutide in Inclusion Body Myositis (IBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Froniglutide in Inclusion Body Myositis (IBM) Drug Details: Froniglutide (formerly PB-1023) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABC-008 in Inclusion Body Myositis (IBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABC-008 in Inclusion Body Myositis (IBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABC-008 in Inclusion Body Myositis (IBM) Drug Details: AB-008 is...